CROs May Offer More Objective Monitoring For Gene Therapy - FDA's Noguchi

Gene therapy clinical trial sponsors may want to consider employing contract research organizations to help achieve more objective and independent monitoring of trial conduct, FDA Cellular and Gene Therapies Division Director Phillip Noguchi, MD, suggested at the Drug Information Association annual meeting June 15 in San Diego.